|
|
5 October 2016 |
Advanced Medical Solutions Group plc
(“AMS”, the “Company” or the “Group”)
Director/PDMR and PCA Shareholding
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), a leading developer and manufacturer of advanced products for the global surgical and wound care markets, announces that it was notified on 30 September 2016 that Eddie Johnson, who is a Senior Manager and PDMR, had exercised 50,000 Ordinary Shares of 5p from the 2009 Executive Share Option Scheme and sold all 50,000 shares.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provide further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1. |
Details of the person discharging managerial responsibilities/person closely associated |
||||
|
a) |
Name: Eddie Johnson |
||||
2. |
Reason for the notification |
||||
|
a) |
Position/status: Senior Manager/PDMR |
||||
|
b) |
Initial notification/Amendment: Initial Notification |
||||
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name: Advanced Medical Solutions Group plc |
||||
|
b) |
LEI: 213800HJP6OWOSZI1L74 |
||||
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||
|
a) |
Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 |
||||
|
b) |
Nature of the transaction: · Exercised 50,000 Ordinary Shares of 5p from the 2009 Executive Share Option Scheme; · Sale of 50,000 shares from the total shares exercised. |
||||
|
c) |
Price(s) and volume(s): Sale of shares:
|
||||
|
d) |
Aggregated information: (Relates to those shares sold only) Aggregated volume: 50,000 Aggregated price: £2.289663 |
||||
|
e) |
Date of the transaction: 30/09/2016 |
||||
|
f) |
Place of the transaction: London Stock Exchange, AIM Market (XLON) |
– End –
For further information, please visit www.admedsol.com or contact:
|
Advanced Medical Solutions Group plc |
Tel: +44 (0) 1606 545508 |
|
Chris Meredith, Chief Executive Officer Mary Tavener, Group Finance Director |
|
|
|
|
|
Consilium Strategic Communications |
Tel: +44 (0) 20 3709 5700 |
|
Mary-Jane Elliott / Jonathan Birt / Matthew Neal / Hendrik Thys |
AMS@consilium-comms.com |
|
|
|
|
Investec Bank PLC (NOMAD & Broker) |
Tel: +44 (0) 20 7597 5970 |
|
Daniel Adams / Patrick Robb |
|
About Advanced Medical Solutions Group plc – see www.admedsol.com
AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical, wound care and wound closure markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it markets under its brands; ActivHeal®, LiquiBand® and RESORBA® as well as supplying under white label.
AMS’s products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in more than 70 countries via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia. Established in 1991, the Company has 510 employees. For more information please see www.admedsol.com.
This information is provided by RNS
END
DSHBBBDGLDGBGLU